Biotech - Drug Development
Biotechnology companies developing novel therapeutics across disease areas (excluding oncology-focused)
Rare Disease Therapeutics150
Neuroscience & CNS90
Immunology & Autoimmune80
Metabolic & Cardiometabolic42
Infectious Disease & Vaccines51
Clinical-Stage Platforms147
| Ticker | Company | Sub-Theme | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | Metabolic & Cardiometabolic | $0.8t | $927.50 | -0.9% | 95.5K |
 JNJ | Johnson & Johnson | Immunology & Autoimmune | $0.6t | $242.30 | -0.3% | 177.2K |
 ABBV | ABBVIE INC. | Immunology & Autoimmune | $377.0b | $207.12 | -0.8% | 75.3K |
 AZN | AstraZeneca PLC | Metabolic & Cardiometabolic | $300.7b | $204.08 | +0.3% | 26.1K |
 MRK | Merck & Co., Inc. | Infectious Disease & Vaccines | $292.0b | $120.81 | -0.0% | 192.5K |
 AMGN | Amgen Inc | Rare Disease TherapeuticsImmunology & Autoimmune | $188.1b | $345.69 | -0.6% | 36.3K |
 TMO | Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $178.3b | $487.83 | -0.7% | 54.2K |
 GILD | Gilead Sciences Inc | Infectious Disease & Vaccines | $169.2b | $139.34 | -0.3% | 79.6K |
 PFE | Pfizer Inc. | Infectious Disease & Vaccines | $158.0b | $27.98 | -1.2% | 1.6M |
 BMY | Bristol-Myers Squibb Co. | Immunology & Autoimmune | $122.0b | $59.07 | -0.9% | 243.2K |
 VRTX | Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $112.6b | $436.16 | -0.6% | 23.6K |
 REGN | Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $79.2b | $760.40 | -0.2% | 18.1K |
 ALNY | Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $41.9b | $330.46 | +3.6% | 64.9K |
 INSM | Insmed, Inc. | Rare Disease Therapeutics | $33.0b | $163.15 | +0.4% | 31.7K |
 A | Agilent Technologies Inc. | Clinical-Stage Platforms | $31.7b | $114.65 | -0.7% | 21.3K |
 WAT | Waters Corp | Clinical-Stage Platforms | $28.8b | $304.57 | +0.1% | 23.8K |
 IQV | IQVIA Holdings Inc. | Clinical-Stage Platforms | $27.9b | $169.70 | -2.0% | 34.3K |
 BIIB | Biogen Inc. Common Stock | Neuroscience & CNS | $27.5b | $176.41 | -0.5% | 20.8K |
 UTHR | United Therapeutics Corp | Rare Disease Therapeutics | $25.8b | $561.66 | -0.6% | 10.9K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $19.9b | $48.03 | -1.1% | 48.5K |
 MRNA | Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $19.1b | $48.93 | -0.6% | 153.4K |
 ROIV | Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $18.9b | $28.18 | -0.5% | 121.1K |
 INCY | Incyte Genomics Inc | Rare Disease Therapeutics | $18.0b | $95.07 | -0.9% | 28.6K |
 WST | West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $17.7b | $253.55 | -0.5% | 5.7K |
 BBIO | BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $13.4b | $73.75 | +0.8% | 15.7K |
 SMMT | Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $13.2b | $19.16 | -1.2% | 77.6K |
 MEDP | Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $13.1b | $487.84 | -2.1% | 7.8K |
 NBIX | Neurocrine Biosciences Inc | Neuroscience & CNS | $12.9b | $127.81 | -2.9% | 195.8K |
 IONS | Ionis Pharmaceuticals, Inc. Common Stock | Rare Disease Therapeutics | $12.0b | $75.02 | +0.3% | 37.8K |
 MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $11.6b | $539.39 | -1.4% | 8.0K |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | Neuroscience & CNS | $11.5b | $31.83 | +3.3% | 14.4K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $11.3b | $185.62 | -0.7% | 8.2K |
 BMRN | BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $10.5b | $55.62 | +0.2% | 20.8K |
 RVTY | Revvity, Inc. | Clinical-Stage Platforms | $9.5b | $88.40 | -0.6% | 6.9K |
 AXSM | Axsome Therapeutics, Inc | Neuroscience & CNS | $8.2b | $169.15 | +0.4% | 7.9K |
 TECH | Bio-Techne Corp. | Clinical-Stage Platforms | $8.1b | $52.50 | -1.2% | 25.5K |
 QGEN | QIAGEN N.V. | Clinical-Stage Platforms | $8.1b | $40.81 | -0.5% | 10.2K |
 ARWR | Arrowhead Research Corporation | Rare Disease Therapeutics | $8.1b | $60.77 | -0.4% | 20.8K |
 ICLR | Icon Plc | Clinical-Stage Platforms | $8.0b | $111.57 | -2.3% | 10.0K |
 PCVX | Vaxcyte, Inc. Common Stock | Infectious Disease & Vaccines | $7.9b | $57.78 | -1.0% | 22.4K |
 CRL | Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $7.9b | $170.94 | -1.7% | 28.3K |
 CYTK | Cytokinetics Inc. | Neuroscience & CNSRare Disease Therapeutics | $7.8b | $65.80 | -1.4% | 47.8K |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | Neuroscience & CNS | $7.7b | $321.02 | +3.4% | 16.2K |
 BIO.B | Bio-Rad Laboratories, Inc. Class B | Clinical-Stage Platforms | $7.5b | $281.50 | +1.2% | 1 |
 HALO | Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $7.4b | $64.31 | -0.3% | 17.6K |
 KRYS | Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $7.2b | $260.40 | -0.2% | 10.3K |
 IBRX | ImmunityBio, Inc. Common Stock | Immunology & Autoimmune | $6.8b | $7.52 | +3.0% | 1.5M |
 KYMR | Kymera Therapeutics, Inc. Common Stock | Clinical-Stage Platforms | $6.5b | $85.12 | -0.3% | 9.4K |
 PTGX | Protagonist Therapeutics, Inc | Immunology & AutoimmuneMetabolic & Cardiometabolic | $6.4b | $103.11 | -0.6% | 9.5K |
 RGEN | Repligen Corp | Clinical-Stage Platforms | $6.3b | $116.85 | -0.8% | 28.3K |